National Cancer Institute
at the National Institutes of Health
Treatment Trials
- Accelerating Clinical Trials of Novel Oncologic PathWays (ACTNOW)
ACTNOW is an initiative in which up to 37 new early-phase cancer treatment trials are being conducted to test the effectiveness of molecularly targeted cancer therapies. - The ALTTO Breast Cancer Trial
(Updated: 10/03/2011) - A collection of material about the Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation, or ALTTO, study that will compare the targeted agents lapatinib and trastuzumab alone, in sequence, or in combination as adjuvant therapy for HER2-positive breast cancer. - The TAILORx Breast Cancer Trial
(Posted: 05/23/2006, Reviewed: 10/22/2010) - A collection of material about the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which will examine whether a molecular test can assign women with early-stage breast cancer to the most appropriate and effective treatment. - Clinical Trials Covered Under the Medicare Anti-Cancer Drugs National Coverage Decision
(Posted: 01/09/2006, Reviewed: 10/07/2010) - Information for patients and doctors about expanded coverage for the experimental and routine services provided to Medicare beneficiaries enrolled in certain cancer trials sponsored by the National Cancer Institute.
Testing and Screening
- National Lung Screening Trial (NLST)
(Updated: 06/29/2011) - A collection of material about the National Lung Screening Trial (NLST), a research study sponsored by the National Cancer Institute that used low-dose helical CT scans or chest X-ray to screen men and women at risk for lung cancer. - Digital Mammographic Imaging Screening Trial
DMIST, the Digital Mammographic Imaging Screening Trial, is a research study sponsored by the U.S. National Cancer Institute to compare digital mammography to conventional screen-film mammography. - Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
A large-scale clinical trial to determine whether certain cancer screening tests reduce deaths from prostate, lung, colorectal, and ovarian cancer. In addition, there are numerous epidemiologic and ancillary studies going on that will answer other crucial questions about these cancers and these screening tests.
